Biren Amin

Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder Drug

Jefferies Calls Bluebird Bio The 'Star' Of This Year's ASH Meeting

Bellicum Pharmaceuticals Q1 Miss Doesn't Matter, As Long As Pipeline Remains On Track

Jefferies Calls Bluebird Bio The 'Star' Of This Year's ASH Meeting

Bellicum Pharmaceuticals Q1 Miss Doesn't Matter, As Long As Pipeline Remains On Track

Low Odds Court Ruling Against Regeneron Get Reversed On Appeal

Jefferies Sees Zynerba Shares More Than Doubling From Here

Low Odds Court Ruling Against Regeneron Get Reversed On Appeal

Jefferies Sees Zynerba Shares More Than Doubling From Here

Kite Pharma Spiking After Release Of Positive Clinical Data

Jefferies Upgrades AveXis To Buy Following Positive AVXS-101 Data, Doc Feedback

Biren Amin Recent News

Jefferies Lifts Target On Medivation To $52 From $39 As 'Xtandi Looking Better'

Buy ImmunoGen On Transformational Products, Jefferies Says

Heron Therapeutics Has Even More Upside, 'Robust' Data Shows

1,800% In Two Days: The Saga Of Aquinox Pharmaceuticals

Kite Pharma Shares Its Vision: Here's How Wall Street Is Reacting

UPDATE: Jefferies Initiates Coverage On Bellicum Pharmaceuticals On Position To Be Leading Player

UPDATE: Jefferies Initiates Coverage On Xenon Pharmaceuticals On Multiple Positive Factors

UPDATE: Jefferies Downgrades Onyx Pharmaceuticals on Limited Upside

UPDATE: Jefferies Initiates Verastem at Buy on Cancer Research Potential

UPDATE: Jefferies Raises PT on Celldex Therapeutics on Key PI/II Catalysts Approaching In Q4

UPDATE: Jefferies Initiates NewLink Genetics at Buy on Immunotherapy Platform Upside